Shanghai Haohai Biological Technology repurchases H-shares

Shanghai Haohai Biological Technology, listed on the Hong Kong Stock Exchange, repurchased 10,000 H-shares on September 16, 2025. The buyback was executed on the exchange at HK$27.68 per share, totaling HK$276,800. This action maintains the company's total issued H-shares (excluding treasury shares) at 38,529,240. The company's total issued shares, including both H and A shares, remained unchanged at 228,733,000.

The buyback reduces the number of H-shares available in the market. As of September 16, 2025, the company's treasury stock (H-shares) remained at zero. The buyback aligns with the company's authorization approved on June 10, 2025, which allows for the repurchase of up to 3,914,184 H-shares. With this latest transaction, the company has repurchased 77,400 H-shares under this authorization, representing 0.1977% of the issued H-shares at the time of the resolution.

The company's next-day disclosure report confirms all regulatory requirements have been met. The company has no immediate plans for new share issuance or sale of treasury shares following this buyback.